D
D D Schoepp
Researcher at Eli Lilly and Company
Publications - 55
Citations - 3114
D D Schoepp is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Metabotropic glutamate receptor & Metabotropic receptor. The author has an hindex of 32, co-authored 55 publications receiving 3043 citations.
Papers
More filters
Journal ArticleDOI
LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors.
A.E. Kingston,Paul L. Ornstein,Rebecca A. Wright,Bryan G. Johnson,Nancy Gail Mayne,J.P. Burnett,Rama M. Belagaje,Su Wu,D D Schoepp +8 more
TL;DR: The in vitro pharmacology of a structurally novel compound, LY341495, was investigated at human recombinant metabotropic glutamate (mGlu) receptor subtypes expressed in non-neuronal cells and represents a novel pharmacological agent for elucidating the function of mGlu receptors in experimental systems.
Journal ArticleDOI
The potent mGlu receptor antagonist LY341495 identifies roles for both cloned and novel mGlu receptors in hippocampal synaptic plasticity
Stephen M. Fitzjohn,Zuner A. Bortolotto,Mary J. Palmer,Andrew J Doherty,Paul L. Ornstein,D D Schoepp,A.E. Kingston,David Lodge,Graham L. Collingridge +8 more
TL;DR: The mGlu receptor antagonist activity of LY341495 is further characterised and this compound is used to investigate roles of mGLU receptors in hippocampal long-term potentiation (LTP) and long- term depression (LTD).
Journal ArticleDOI
Induction or protection of limbic seizures in mice by mGluR subtype selective agonists.
TL;DR: The data indicate that mGluR agonist-induced limbic seizures in mice are mediated by activation of phosphoinositide-coupled m GluRs, and these seizures can be protected against byactivation of mGLURs that are negatively-linked to cAMP formation.
Journal ArticleDOI
Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
TL;DR: The activation of bothmGlu2 and mGlu3 receptors by LY354740 appears to be required for anxiolytic-like activity in the EPM test in mice, and these studies serve as a foundation for additional studies on underlying circuits, brain structures, and receptor subtypes involved in the anxiety-related actions of mGLU receptor active agents, and the design of future drugs for anxiety disorders in humans.
Journal ArticleDOI
Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions.
TL;DR: The suppression of fear-evoked neuronal activity in the hippocampus and drug-induced increases in neuronal activation in the CeL have been previously linked to the anxiolytic effects of clinically effective drugs such as benzodiazepines, and thus may contribute to anxioleytic actions of LY354740 in animal models and human anxiety patients.